Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ASCO 2023 Expert Report on novelties in the treatment of gynaecological malignancies, by P. Harter

Reporting from ASCO 2023 Annual Meeting, Philipp Harter discusses the results from the SHAPE trial evaluating both outcome and quality of life at 3 years of simple vs radical hysterectomy in low-risk early stage cervical cancer. He also presents some encouraging PFS results from the interim analysis of the DUO-O trial, testing the addition of durvalumab alone and in combination with olaparib to the PC plus bevacizumab regimen, in advanced Ovarian Cancer without a BRCA1/2 mutation. Further analysis and longer follow-up are needed to confirm these results, and the potential benefit in the HRD negative population.

Abstracts discussed:
- LBA5511: An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
- LBA5506: Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.